Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 Study

20260 citationsJournal Article

Authors

Emmanuel S. Antonarakis · University of Minnesota

Qing Cao · University of Minnesota

Victoria Catharine · Memorial Sloan Kettering Cancer Center

Benedito A. Carneiro · Brown University

Andre Luiz De Souza · Brown University

David James VanderWeele · Northwestern University

Parminder Singh

Abstract

Cabazitaxel and carboplatin followed by abiraterone, together with ADT, was feasible, safe, and efficacious in patients with high-volume mCSPC, and warrants further study in larger randomized trials.

Topics & Keywords

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment PARP inhibition in cancer therapy

Publication Details

Published in: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-25-4823

Field-Weighted Citation Impact: 0.00

Command Palette

Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 Study

Authors

Abstract

Topics & Keywords

Publication Details